Key result
Single-agent pixantrone achieves a ~27% overall response rate in relapsed aggressive non-Hodgkin lymphoma.
Why the study?
Does pixantrone improve response rates and reduce cardiac toxicity in patients with relapsed aggressive non-Hodgkin lymphomas compared to alternative anthracyclines?
Does pixantrone improve response rates and reduce cardiac toxicity in patients with relapsed aggressive non-Hodgkin lymphomas compared to alternative anthracyclines?
Pixantrone shows promising efficacy with significantly lower cardiac toxicity compared to traditional anthracyclines in the treatment of non-Hodgkin lymphomas.
May warrant testing in cardiotoxicity-prone lymphoma regimens; leaves open confirmation in randomized trials.
Pixantrone (BBR2778) is a novel anthracycline derivative, manufactured by Cell Therapeutics Incorporated, WA, USA. In both preclinical and clinical studies pixantrone exhibited a significantly lower cardiac toxicity and better activity than that observed with alternative anthracyclines, as it is devoid of the putative cardiac toxicity generating 5,8-dihydroxy groups. With single-agent pixantrone, neutropenia was the dose-limiting toxicity. In relapsed aggressive non-Hodgkin lymphomas, weekly single-agent pixantrone 85 mg/m(2) for 3 weeks every 4 weeks was associated with a 27% overall response rate and a 15% complete response rate. When used in combination with chemotherapy regimens overall response rates of 58-74% and complete response rates of 37-57% were achieved.
No takes yet. Share an insight, caveat, or question.
El-Helw et al. (2009) conducted a review in relapsed aggressive non-Hodgkin lymphomas. Pixantrone was evaluated on overall response rate. Single-agent pixantrone achieved a 27% overall response rate and 15% complete response rate in patients with relapsed aggressive non-Hodgkin lymphomas.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: